Merck's earnings call revealed mixed performance.  While some new products showed strong growth, particularly internationally, key brands like Gardasil and Singulair experienced challenges.  Management's cautious tone regarding the SEAS study, along with revised guidance for several products, suggests short-term uncertainty, potentially impacting the stock price negatively in the coming weeks.
[-1]
